Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel group, placebo-controlled, multicenter, phase 2 trial

医学 过敏性支气管肺曲菌病 伊曲康唑 哮喘 安慰剂 不利影响 随机对照试验 内科学 临床终点 过敏 气道 免疫球蛋白E 临床试验 喘息 曲菌病 吸入 麻醉 气道阻塞 免疫学 烟曲霉 临床研究阶段
作者
Ritesh Agarwal,Dhruv Chaudhary,Shyam Narain Gupta,Raja Dhar,Pajanivel Ranganadin,Rohit Kumar,Ajay Mohan,Jyoti Bajpai,Rennis Davis,Inderpaul Singh Sehgal,Pawan Singh,Beauty Biwas,Saurabh Mittal,A J Mahendran,Boney Rajan,Sonali Jadhav,Abhijit Vaidya,Sushmeeta Chhowala,Sandesh Sawant,Jaideep A. Gogtay
出处
期刊:The European respiratory journal [European Respiratory Society]
卷期号:: 2600058-2600058 被引量:2
标识
DOI:10.1183/13993003.00058-2026
摘要

Background No therapies are approved for allergic bronchopulmonary aspergillosis (ABPA), which affects an estimated 4.8 million asthmatic individuals worldwide. Current treatment with oral corticosteroids or oral itraconazole is limited by systemic toxicities, drug-drug interactions, and suboptimal airway drug concentrations. PUR1900 is a novel inhaled itraconazole formulation designed to achieve high airway concentrations with minimal systemic exposure. Methods We conducted a phase 2, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial. Adults with asthma and ABPA were randomized (2:2:1) to receive inhaled PUR1900 20 mg, PUR1900 40 mg, or placebo once daily for 16 weeks. Key eligibility criteria included serum total IgE ≥1000 kU·L −1 , Asthma Control Questionnaire (ACQ)-7 score >1.5, and pre-bronchodilator FEV 1 50–85% predicted. The study had no prespecified primary endpoint and evaluated multiple exploratory outcomes across lung function, immunological, and patient-reported domains. Results We randomized 43 participants (20 mg, n=18; 40 mg, n=16; placebo, n=9); 39 completed treatment. Baseline characteristics were balanced. At week 16, PUR1900 40 mg was associated with placebo-adjusted improvements in FEV 1 (LSM +0.28 L; 95% CI: 0.02, 0.53) and ACQ-7 (LSM −0.51 points; 95% CI: −0.97, −0.06), with reductions in serum total IgE (LSM −2619 kU·L −1 ; 95% CI: −5342, 105). No placebo-adjusted effects were observed with PUR1900 20 mg. Adverse events occurred in 31%, 39%, and 44% of participants receiving 40 mg, 20 mg, and placebo, respectively; none were serious. Conclusions PUR1900 40 mg was associated with improvements across key clinical domains in ABPA, with a favorable safety profile, supporting further phase 3 evaluation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
edk发布了新的文献求助10
刚刚
灵兰发布了新的文献求助10
刚刚
1秒前
zhao发布了新的文献求助10
1秒前
1秒前
晴qq发布了新的文献求助10
2秒前
充电宝的应助被电灯胆采纳,获得10
3秒前
阿乐完成签到 ,获得积分10
3秒前
3秒前
姚y1234_完成签到,获得积分20
3秒前
rainbow完成签到,获得积分10
6秒前
7秒前
7秒前
8秒前
ccxr发布了新的文献求助30
8秒前
enoblin完成签到,获得积分10
8秒前
啦啦啦完成签到 ,获得积分10
8秒前
9秒前
9秒前
9秒前
9秒前
研友_VZG7GZ的应助被危机的盼晴采纳,获得10
9秒前
10秒前
10秒前
11秒前
爆米花的应助被xszlll采纳,获得10
11秒前
11秒前
顺利毕业完成签到 ,获得积分10
12秒前
xuemei完成签到,获得积分10
12秒前
运气不错完成签到,获得积分20
12秒前
郑睿涛发布了新的文献求助10
12秒前
12秒前
梦晨完成签到,获得积分10
13秒前
deng的应助被oosr采纳,获得10
13秒前
13秒前
Kyle发布了新的文献求助10
14秒前
思源的应助被科研通管家采纳,获得10
14秒前
秋风的应助被科研通管家采纳,获得10
14秒前
科目三的应助被科研通管家采纳,获得10
15秒前
隐形曼青的应助被科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611